Health System AI Platforms

symplr is the largest company assessed in this part of the index and the one furthest from the bedside. It sells healthcare operations software: credentialing and provider data management, workforce scheduling and timekeeping, contract lifecycle and spend management, vendor access control, and compliance, quality and safety. The framing the company and its investors use is governance, risk and compliance for healthcare, and that is an accurate description of what a buyer is purchasing. It is enrolled rather than screened because it is healthcare exclusive and because the models are real and specific. It sits at the outer boundary of this index by subject matter, not by whether it ships intelligence. Three artificial intelligence capabilities are concrete enough to assess. Smart Square, the workforce product acquired from AMN Healthcare in 2025 for roughly $75M and now merging with the existing workforce product, applies predictive analytics and real time record system driven data to nurse and staff scheduling, aligning staffing to forecast patient demand, and has been recognised by an independent healthcare research firm as a leader specifically for that predictive capability. Contract lifecycle management gained conversational access to contract data plus assisted review and redlining that flags risk and suggests edits. Vendor access gained automated credential verification through a smart badge that replaces manual kiosk check in with real time compliance tracking. Provider data management, the product that competes most directly with Kyruus Health, maintains directory accuracy and network management for health plans against their regulatory obligations. Scale is the defining fact and it is very large. Deployments in nine of ten United States hospitals, more than 400 health plans, and over 6,000 customer locations. The platform runs on Amazon Web Services infrastructure, launched as a unified operations platform in February 2025 after years of the portfolio being separate products. The company was founded in 2006 in Houston, Texas, and is privately held under Clearlake Capital and Charlesbank Capital Partners with SkyKnight Capital, following an ownership history that includes Francisco Partners and earlier sponsors. It has completed at least nine acquisitions since 2018, which is what produced the breadth, and is led by chief executive BJ Schaknowski. Two things a reader should weigh. This is a buy and build platform, so the products carry different heritages and nothing published describes how far the underlying technology has been unified beyond the shared platform layer; a buyer should establish which module carries which lineage. And the artificial intelligence sits in operations rather than in care, so a hospital evaluating this is assessing whether models should influence who is scheduled to work and which contracts get flagged, not whether models should influence a patient's treatment. Those are different questions and the second is not asked here.

Inovalon is a data business that sells analytics, and the data asset is the reason it matters. The MORE2 Registry, its Medical Outcomes Research for Effectiveness and Economics dataset, is described as drawing on more than 160 primary sources across all fifty states and holding upwards of 99 billion medical, pharmacy and laboratory events covering 1.1 million clinicians and hundreds of millions of unique lives. The company is also a Qualified Entity under the Centers for Medicare and Medicaid Services programme of that name, which permits access to complete Medicare fee for service data for defined purposes. Very few organisations hold a comparable position, and everything else the company sells rests on it. Inovalon ONE is the platform layer, combining national scale connectivity to electronic health record systems and health information exchanges with real time primary source data and analytics, and it carries more than 100 software solutions reached through a single sign on portal. Four buyer markets are served from it. Payer products centre on Converged Quality, which supports quality measurement, reporting and improvement across HEDIS, Medicare star ratings and state programmes. Provider products, built on the acquired ABILITY Network and now the Provider Cloud, cover revenue cycle, care quality and workforce management. Pharmacy products serve specialty and infusion operations. Life sciences products license data and analytics for research, health economics and trial work. This record grades the company as one entity because a single platform, a single data asset and a single compliance posture underlie all four lines. Two ownership points sit alongside it. VigiLanz, acquired in February 2024 and graded separately in this index, is still sold under its own name and its record documents the ownership. And Inovalon was taken private in August 2021 at an enterprise value of roughly 7.3 billion dollars by a consortium led by Nordic Capital with Insight Partners, 22C Capital and founder and chief executive Keith Dunleavy. The external validation record is the strongest in this lane. Converged Quality earned its twenty sixth consecutive National Committee for Quality Assurance measure certification in July 2026 together with validation of its digital quality measure engine, and took the 2026 category award for quality measurement and reporting analytics in a research firm's customer survey. The company states more than 100 health plans use the product, representing a majority of enrolment in four star and above Medicare Advantage plans, alongside more than 50,000 licensed customers overall. Headquartered in Bowie, Maryland. Two things a reader should weigh. Data gathered while serving payers and providers also supports a licensing business selling data and analytics to pharmaceutical and life sciences customers, and no published statement explains what permissions govern that second use. And no pricing of any kind was located.

Persivia sells accountable care organisations and health plans a single platform for running risk contracts, and the platform carries a longer history than its current positioning suggests. CareSpace aggregates clinical records, claims, health information exchange feeds, admission and discharge messages, patient reported data, home device readings and social determinants information into a longitudinal patient record, then layers risk stratification, care management, quality reporting, care gap identification and patient outreach on top of it. The company describes the product as built on more than a decade of clinical rules engine and analytics work combined with clinical content expertise, which is an unusually candid account of its own lineage and matters for how the intelligence claims should be read. The content library is the distinguishing asset. More than 200 evidence based programmes cover chronic disease management, care transitions, preventive care, behavioural health and social determinants, each combining a care pathway with analytics, and customers deploy them as shipped or adapt them to local practice and payer requirements. Buying a configured programme rather than building a protocol is the difference between going live in weeks and going live in quarters, and the company claims a data pipeline operational in eight weeks against a stated industry norm of six to twelve months. Patient contact is automated and the company is direct about why. Software agents conduct natural language text message and voice outreach for follow ups, appointment reminders, medication adherence and chronic care education, described explicitly as keeping patients engaged without requiring additional staff capacity. Social determinant flags drive targeted outreach to groups least likely to meet outcome thresholds. External credentials are held rather than asserted. The company earned the Certified Data Partner designation in the National Committee for Quality Assurance Data Aggregator Validation programme in January 2025, the same credential Arcadia holds, and CareSpace secured HITRUST implemented one year certification in March 2024. Earlier recognition includes a best decision support system award for accountable care organisations from an industry survey firm. Founded and led by clinician entrepreneurs, headquartered in Marlborough, Massachusetts, and recapitalised in April 2025 in a 107 million dollar transaction with Aldrich Capital Partners, which holds the company alongside Petrichor Healthcare Capital Management. Two things a reader should weigh. The most specific outcome figures attached to this platform, including a shared savings result, a national ranking among Medicare Shared Savings Program participants and a large readmission reduction, appear in a comparison of the top eight platforms in this market published by Persivia itself, which is a vendor ranking a field that includes the vendor. And no pricing of any kind was located.

Health Catalyst sells health systems the data layer beneath their improvement work, plus the people to run it. The company describes two operating segments in its filings. Technology is the larger and covers a cloud data platform, analytics applications and support, sold as cloud subscriptions and term licences. Professional Services covers analytics, implementation, strategic advisory, outsourcing and improvement services, positioned as the expertise a customer needs to configure and actually use the technology. That structure is the defining fact about this company: the improvement outcomes it markets are attributed to the combination of software and expert labour rather than to software alone. Ignite is the current platform. It ingests electronic health record, claims, financial and operational data through prebuilt source starter sets, profiles it for quality, resolves patient and provider identity, and exposes a unified data model that customers query with their own business intelligence and modelling tools if they prefer. Ignite Intelligence, introduced in 2025, layers shared models, software agents, benchmarks and comparison services on top. Clinical Cost Intelligence is the flagship example and its published method is unusually specific for this lane, combining supply normalisation, ontology mapping, machine learning driven variation analysis and large language model assisted opportunity screening to move service line costing from months of analysis to immediate results. Healthcare.AI is sold as a mix of self service model building products and expert services covering analytics integration, model selection and model optimisation. Much of the estate arrived by acquisition and is co branded rather than absorbed. Twistle, Upfront and Lumeon are all sold as products by Health Catalyst, a patient engagement tool, a patient experience platform and a care orchestration engine respectively. An interoperability and health information exchange suite carries the company name after having been acquired as Medicity. Registry, quality measure and revenue cycle applications sit alongside them. Security disclosure is the strongest part of the public record. A dedicated information security page enumerates which certifications cover which named products, with framework versions and explicit coverage periods, spanning HITRUST certification across three business unit product families and audited reports at the type two assurance level. Recertification has continued through 2025 across the acquired brands. More than 1,100 organisations are stated to use the offerings, across hundreds of millions of patient records. Headquartered in Salt Lake City and listed on the Nasdaq exchange. Three things a reader should weigh. Trailing twelve month revenue stood at roughly 302 million dollars as of March 2026 against a market capitalisation of roughly 154 million dollars at the end of July 2026, a company valued below one year of revenue, and a buyer signing a multi year data platform contract should form its own view of what that indicates. Revenue growth is described as modest with full year guidance reduced and restructuring under way. And the headline claim of billions of dollars in measurable results appears across company material with no method, no time period and no breakdown.

Arcadia sells the data foundation underneath value based care, and increasingly the models that run on top of it. The platform ingests clinical records from electronic health record systems, payer claims, admission and discharge feeds, pharmacy data and social determinants information, resolves them to a single member through a proprietary master patient index, applies natural language processing to unstructured text, and presents the curated result to population health, risk, quality and network teams. Named components include a data gateway that handles ingestion and monitors for quality anomalies, a lakehouse platform layer, Arcadia Vista for value based care insights, Network Modeler, Contract IQ, Provider Intelligence, and an AI Factory positioned as an analyst facing environment for building predictive models on a customer's own data. A point of care assistant is the company's first generative artificial intelligence product. Two ownership events shape what the company is now. CareJourney, acquired in June 2024, supplied national benchmark data derived from Medicare claims, which gave Arcadia an external comparison set rather than only the data its customers bring to it. In July 2025 Nordic Capital took ownership. The brand is still sold under its own name and the product line has expanded since, so the change of owner does not alter how this record reads. Credentials in the quality domain are held rather than asserted. The company earned the Certified Data Partner designation in the National Committee for Quality Assurance Data Aggregator Validation programme, and separately a Validated Data Stream designation covering the use of its clinical data for HEDIS performance measurement. That second one matters more than it sounds, because it means an external body examined whether data flowing through this platform is fit to be scored on rather than taking the vendor's word for it. Security credentials are long standing: ISO 27001 in 2017, a SOC 2 Type One report in 2019, HITRUST CSF certification in 2020, and top ratings across every category in an independent cybersecurity preparedness evaluation conducted by KLAS Research and Censinet, an exercise roughly ten percent of eligible vendors agreed to enter. Buyers are health systems, provider groups, accountable care organisations and health plans operating under shared savings, ACO REACH, Medicaid and commercial risk contracts. Named customers include Southwestern Health Resources, Tandigm, Castell, Rush Health and Beth Israel Lahey Health. Three things a reader should weigh. The published outcome figures, including 81 percent in visit diagnosis capture, 59 percent more closed risk per patient and a 24 percent reduction in inpatient admissions, carry no denominator, no time period and no stated method. The most recent security report located is a SOC 2 Type One rather than a Type Two, which tests whether controls are designed correctly rather than whether they operated correctly over a period. And a dedicated pass located no pricing of any kind.

Clarify Health sells predictions built on one of the largest linked healthcare datasets in the United States. The Clarify Atlas Platform maps longitudinal patient journeys across more than 300 million unique lives, assembled from health plan claims, pharmacy data, government sources and negotiated pricing rates, and generates a stated 20 billion or more machine learning predictions on top of it. Applications sit above that foundation as modular building blocks, covering provider network design and optimisation, referral pathway analysis, cost containment, quality and utilisation assessment, population health, value based care performance and pharmaceutical commercialisation. The method has been described by the company's own leadership as applying the analytical approach popularised in professional sports to healthcare, objectively assessing hospital and clinician performance and connecting clinical results to financial incentives. A Performance IQ Suite launched in October 2024 spans cost, quality and utilisation together, using machine learning and natural language processing, and a separate product supports referral network optimisation and care pathway analytics. Buyers span the ecosystem rather than one segment: health systems, physician groups, ambulatory surgical centres, health plans, technology and services organisations, and life sciences companies. Independent recognition is substantial and consistent. A major analyst firm ranked the company first for data analytics platforms serving payers, and a large software marketplace named the platform the top vendor in its relationship index for healthcare analytics in its Winter 2025 report, alongside high performer and momentum leader designations, all derived from customer reviews. Based in San Francisco and led by chief executive Jean Drouin with founder and president Todd Gottula. Roughly 411 million dollars has been raised across ten rounds from 24 investors, including a 150 million dollar round in 2022 at a valuation of 1.4 billion dollars. Three things a reader should weigh. Headcount stood at 116 as of March 2026, which is small relative to the capital raised and the valuation recorded in 2022, and a buyer should form its own view of what that indicates. A headline claim of 2.6 billion dollars in customer verified return appears throughout company material with no method, no verification process and no per customer breakdown disclosed. And a dedicated pass located no named customer, no security attestation, no data handling statement and no account of where the 300 million life dataset comes from or on what legal basis it is assembled.

ClosedLoop builds predictive models for healthcare organisations and explains them. The platform supplies off the shelf models for common use cases, automates the data preparation that consumes most of a healthcare data scientist's time, and produces individual level risk predictions rather than population scores. Named applications include predicting admissions and readmissions, total utilisation and total risk, emergency department over utilisation, out of network utilisation, appointment non attendance, and the onset or progression of chronic disease. The distinguishing credential is competitive and adjudicated rather than self reported. In April 2021 the company won the grand prize in the Centers for Medicare and Medicaid Services Artificial Intelligence Health Outcomes Challenge, a multi stage competition begun in 2019 and run by the agency's innovation centre with the American Academy of Family Physicians and Arnold Ventures. It beat more than 300 entrants including IBM, Mayo Clinic, Merck, Accenture and Deloitte, with Geisinger the runner up. What the challenge asked for matters as much as who won it: the brief was explicitly for explainable artificial intelligence that front line clinicians could understand and trust, applied to predicting unplanned admissions and adverse events among Medicare beneficiaries. An independent federal body ran a two year contest on explainability and this company came first. That design shows in the product. Each Patient Health Forecast presents a prediction alongside the specific variables driving it and links to interventions a clinical team can act on, so a clinician receives a reason and a next step rather than a number. Independent recognition continued afterwards, with the top rating in a major analyst firm's healthcare artificial intelligence data science category in 2022, 2023 and 2024. Published work includes an open sourced vulnerability index released during the pandemic, documented in a medical artificial intelligence journal and stated to have reached more than 10 million lives, and a collaboration with a value based primary care provider published in a clinical management journal. Named customers span a large nonprofit health plan, the largest Medicaid accountable care organisation, a long term care accountable care organisation, physician groups and a federal contractor. Based in Austin, Texas, with roughly 48 million dollars raised including a 34 million dollar Series B in August 2021. Two cautions. One named customer also participated as an investor in that round, so any reference from it carries a commercial interest. And no company announcement, funding event or product release was located after February 2024, which is a gap a buyer should resolve directly before relying on current capability. No pricing, security attestation or data handling statement was found.

Huma sells a regulated platform that other organisations configure into their own clinical software. The Huma Cloud Platform is a disease agnostic and device agnostic software as a medical device, cleared as a configurable framework rather than as a single product, so a hospital, national health system or pharmaceutical sponsor can assemble a regulated disease management tool from pre built modules with no code and deploy it in weeks rather than running a multi year regulatory programme of its own. Partners inherit the clearance. That clearance is the most extensive in this index. The platform holds simultaneous status across six jurisdictions: United States Class II under the 510(k) route, European Union Class IIb under the current medical device regulation, United Kingdom Class IIb registration, Australian, Saudi and Indian approvals, with a Health Canada Class II licence added subsequently. The United States clearance permits monitoring patients of any age with any condition, explicitly including paediatrics and pregnancy, and the platform is regulated to host artificial intelligence and machine learning models rather than only fixed logic. Five layers sit on that base: remote patient monitoring and companion apps, decentralised clinical trials, Hi Scribe for generative clinical documentation, an agentic layer marketed as Huma Intelligence, and direct to consumer virtual care. A software development kit lets partners embed functionality into their own products, and the hosting framework is described as cloud agnostic. Scale is substantial and geographically wide. Company material has reported more than 3,000 hospitals and clinics, over 1.8 million active users in care delivery and more than 650,000 research participants, with the platform used to build software across more than 70 countries. Published case work includes an emergency department triage deployment in a London hospital, a decade long oncology real world evidence study, a lung cancer screening programme validating a risk model that has become part of a national screening blueprint in Germany, a non interventional insomnia study across Germany and Austria, and a kidney and diabetes research programme that recruited 4,500 patients a year ahead of schedule. Huma Therapeutics Limited is based in London with New York operations and is led by founder and chief executive Dan Vahdat. Series D financing closed in July 2024 taking total funding past 80 million dollars, with investors including the venture arm of a major pharmaceutical group. Two things a reader should hold. The strongest asset here is regulatory and architectural rather than algorithmic: the platform's distinguishing property is that it is cleared and configurable, and much of the artificial intelligence running on it belongs to partners. And two dedicated passes located no pricing of any kind, no information security certification and no customer facing trust centre, with the clearest account of data handling appearing in a clinical trial protocol rather than in anything a prospective buyer would find.

Caregility runs the video layer of the hospital and is adding intelligence on top of it. Caregility Cloud, now presented as the Caregility Connected Care Platform, delivers secure two way audio and video into patient rooms across inpatient, ambulatory, post acute and home settings, and applications sit on that layer for specific jobs: iObserver for virtual observation and e sitting, iConsult for virtual consultation, and iCare Coordinator for coordinating bedside clinicians, remote caregivers and AI tools in one place. The scale is larger than any comparable vendor in this index. More than 1,500 hospitals and 75 health systems across multiple continents, over 30,000 connected devices, and more than six million virtual sessions a year. Programmes span virtual nursing, virtual observation, virtual rounding, specialty consults, operating room telehealth and hospital at home. The artificial intelligence is real and is being built rather than inherited. Edge based computer vision runs on the devices, audio sensing detects room duress, and ambient listening and sensor based capabilities are in the platform, with an AI enhanced unlimited patient monitoring capability added to the coordination application in 2026. The 25.1 million dollars raised in September 2025, led by Star Mountain Capital and bringing total outside investment to 92 million, was explicitly earmarked for computer vision, ambient listening and sensor technologies. A Chief Product, Technology and AI Officer holds the portfolio. Integration is the strongest part of the record. Caregility has been listed in Epic Toolbox for Inpatient Virtual Care for two consecutive years including 2026, with named integration paths into MyChart Bedside TV, Epic Monitor, Haiku and Hyperspace, alongside nurse call systems, interactive patient consoles and bedside devices. Ecosystem partners run their own applications on the platform, with a clinical documentation vendor among those named. Connectivity options extend to 5G and satellite for rural and mobile deployment. Compliance disclosure is also stronger than the segment norm. The platform is stated to be HIPAA, GDPR and CCPA compliant and ISO and SOC certified, and a named independent security firm is cited as having verified the HIPAA position. The platform has been recognised as the leading virtual care platform outside the record system vendors by a third party analyst firm in three consecutive years. Based in Wall, New Jersey. One thing a buyer should weigh directly. The footprint here is larger than the closest competitor's and the published evidence is thinner: no peer reviewed study was located, and named customer results are testimonial rather than quantified, where the closest competitor publishes response times, alarm reductions and dollar figures at named institutions. Scale and evidence are different things and this record separates them deliberately.

AvaSure invented virtual sitting and has spent fifteen years turning it into an enterprise platform. A camera in the patient room feeds a remote observer who can speak to the patient through two way audio and summon staff, and computer vision watches alongside that observer, flagging potential falls and other high risk events so attention lands where it is needed. The ratio is the product: a single observer safely covers up to 16 patients, which is what converts one to one sitting into something a hospital can staff. The platform now spans continuous observation, virtual nursing, episodic consults, virtual visits, ambient sensing and an AI agent for virtual care workflows. Hardware comes in fixed and mobile forms, with 1080p cameras carrying 10x optical zoom and 360 degree pan, tilt and zoom, infrared illumination for night vision, and a dual camera variant pairing a wide angle lens for ambient signal capture with a second lens for video consults. Ceiling mounted units are tamper resistant and available in ligature safe configurations for behavioral health. Integration is the part that separates this from a camera system. The virtual visit application launches from within Epic Hyperspace, devices pair with Epic Monitor for virtual observation, and urgent alarms route to nurse call systems in real time over HL7 interfaces, application programming interfaces or middleware. Caregiver acknowledgements then sync back into AvaSure, which closes the loop and makes response measurable rather than assumed. Scale and evidence are both unusual for this index. More than 1,200 hospitals are deployed. A peer reviewed study published in early 2026 evaluated a continuous virtual monitoring programme in a long term acute care hospital across 40 months, reporting sustained safety and financial outcomes. Named customer results include a 38 percent reduction in urgent alarm rates with an 11 second average response time at one health system, and a 16 percent cut in emergency department holding time with a 31 percent improvement in discharge turnaround at an urban safety net hospital. More than 150 customer generated presentations and studies exist, and one health system published 3.2 million dollars in measurable impact. The company began in Grand Rapids, Michigan as a business security integrator and launched the TeleSitter line in 2009, adding a team of registered nurses who run the clinical education programme that accompanies the technology. Importantly for membership here, AvaSure sells the platform and the hospital staffs the observers, which is what distinguishes it from managed monitoring services that supply observers from their own centre. One disclosure worth knowing before procurement. AvaSure publishes no rate card, but a United States Department of Veterans Affairs solicitation sets out the commercial structure in the open: software licensed per hardware device on an annual term at a named tier, with support tiered separately, and hardware, clinical services, monitor stations and installation carried as distinct line items. A federal variant of the hardware carries validated cryptography.

Virtual care collaboration platform repositioned around agentic artificial intelligence, sold as ThinkAndor. Founded 2018 in Orlando, Florida. Microsoft's venture arm took an investment position in 2020 and the two work closely on the underlying model technology. The platform is organised around five pillars of virtual health: virtual visits, virtual hospital, virtual patient monitoring and care management, virtual team collaboration, and virtual community collaboration. In practice that spans device agnostic virtual rounding, virtual nursing and virtual sitting, remote specialty consults including tele stroke, tele psychiatry and tele intensive care, smart room deployments, digital front door agents and conversational patient interaction. The company describes generative capability for ambient sensing and conversational documentation, pulling patient and clinical context out of source systems into the virtual encounter and pushing recommended tasks back into the record. Third party validation is the strongest part of this record and is unusually well quantified. ThinkAndor was rated 2026 Best in KLAS for virtual care platforms in the non record system category, with a published score of 95.9 out of 100, which the company states is 15.7 points above the overall average and 15.1 points above the virtual care platform average. Black Book has rated it the highest scoring virtual care platform in the same category for three consecutive years, and Frost and Sullivan recognised it in 2025 for acute care virtual health. Two national group purchasing agreements are in place, with Vizient from February 2025 and Premier from February 2026. Scale is stated at more than 70,000 providers and more than 500 hospitals across the United States, Canada and the United Kingdom. Named deployments include Sentara Health across twelve hospitals from November 2025, Providence, and the National Institutes of Health Clinical Center. Published outcome claims are vendor stated and are not backed by any study located in this pass: ten to twelve minutes saved per visit, a 35 percent reduction in call abandonment, reduced call centre utilisation, and a 47 percent reduction in readmissions attributed to intelligent orchestration of patient care. The readmission figure in particular is a substantial clinical claim carrying no published evidence, and should be treated as marketing until a source is produced. One sourcing note. The clearest statement of the underlying model technology, that the Microsoft relationship optimises virtual interactions using that company's partnered large language models, appears on a third party health system marketplace listing rather than in the company's own material, and is recorded on that basis.

Enterprise patient flow, electronic patient record and clinical decision support software, and the only vendor in this index whose business sits almost entirely outside the United States. Listed on the Australian Securities Exchange, led by managing director and chief executive Kate Quirke. All figures below are Australian dollars. The platform is Miya Precision, positioned as modernising legacy health systems by standardising data across complex environments and delivering real time clinical decision support on top of it. Coverage spans patient flow and bed management, command centre operations, emergency department workflow, care coordination, virtual care and, increasingly, full electronic patient record deployments. In June 2026 the company completed the acquisition of the Kyra flow products from Telstra Health, adding 33 customers of which 31 were new and consolidating its position in the Australian patient flow market. Scale is documented rather than claimed, because listing obliges it. The platform runs across more than 400 hospitals globally, supporting more than 50,000 beds and 130,000 active users. Customers include more than 40 National Health Service trusts in the United Kingdom, healthcare providers in every Australian state and all four regions of New Zealand Health, with stated expansion interest in Canada and the Middle East. Named customers include University Hospitals Sussex, Harrogate, Northumbria, Dartford and Gravesham, Hywel Dda and Western Health, the last of which renewed for a fifth time across twenty years. Financial disclosure is unmatched in this index. Revenue for the year ended 30 June 2026 was 51.6 million dollars, up 27 percent, split 63 percent United Kingdom and 37 percent Australia and New Zealand, with annual recurring revenue of 38.3 million dollars up 34 percent and a record 78.5 million dollars of new and renewal total contract value. Individual contracts are disclosed: the May 2026 University Hospitals Sussex electronic patient record agreement runs seven years at roughly 35 million dollars, extendable to roughly 49 million dollars over ten. The artificial intelligence is a layer rather than the product. The company describes a growing suite of generative capabilities inside Miya Precision covering clinical documentation, summarisation and problem detection, and management frames the platform as one that standardises data and helps deploy algorithms safely in regulated healthcare settings. That framing is close to the infrastructure position this index rejects elsewhere, and the record sits inside the boundary because the company builds its own decision support and generative capability rather than solely carrying other parties' models. The centrality grade reflects the balance. Two record keeping notes. The specific city of headquarters was not confirmed in this pass, and neither was the founding year, so both are omitted rather than guessed. And two axes in this framework, the federal privacy posture and the device regulator status, assume a United States vendor and map poorly here; both are graded against the equivalent obligation in the company's actual markets and the reasoning is recorded on each.

Patient flow and capacity management for hospitals and health systems, and the incumbent against which LeanTaaS and Qventus are usually evaluated. Headquartered in Pittsburgh, operating for more than three decades, with a reported 369 employees and a stated global footprint of more than 200,000 managed beds representing millions of patient stays annually across North America and Europe. The product is the Operations IQ Platform, rebranded in October 2024 as the company completed a move from installed software to a hosted model. Capacity IQ handles bed management, discharge efficiency, turnover and emergency department boarding. Workflow IQ covers perioperative settings. Transfer IQ manages patient transfers within and between facilities. Referral IQ connects owned and affiliated referring providers. Data IQ delivers enterprise analytics. Underneath sits three decades of workflow automation, transport dispatch and real time location technology, which the company combined with patient flow software to create a real time capacity platform. The artificial intelligence is recent and is one module among several. Decision IQ launched on 20 November 2025 as what the company describes as the first artificial intelligence driven solution for managing patient flow at scale, replacing retrospective reporting with forward looking system wide visibility so teams can anticipate throughput constraints before they bite. University of Louisville Health is the named early adopter, expanding a longstanding transfer operations relationship. The company's own framing pairs more than thirty years of operational expertise with advanced artificial intelligence, which is an accurate description of the balance and is the reason the centrality grade on this record sits low. Membership was decided on the centrality grade rather than the reject filter, following the Aetion precedent. This is a healthcare only technology company rather than a horizontal vendor and it is not a services business, so neither of those filters applies. What is true is that most of the platform would function without a model, and that is recorded on the axis built for it rather than treated as disqualifying. Ownership note requiring verification before quotation: one vendor database records the company as acquired by an entity named Aionex, and no confirming source was located. The brand plainly survives under its own name regardless, carrying its own domain, its own current copyright, its own product line and a November 2025 product launch in its own name, so the acquired vendor ruling is satisfied either way. The gap across this record is disclosure rather than capability. A dedicated pass located no security certification, trust page, privacy posture, pricing information, integration specification or published outcome figure for the artificial intelligence product. For a vendor of this tenure and installed base, that is a striking amount of nothing.

DeepHealth is the umbrella brand for RadNet's Digital Health segment and the entity that contracts RadNet's clinical AI and imaging informatics software to third party providers. It is a wholly owned subsidiary of RadNet, Inc. (NASDAQ: RDNT), headquartered in Somerville, Massachusetts, and the brand was launched in November 2023 to consolidate a sequence of acquisitions. Those absorbed brands are named here because this index has no aliases field and they are otherwise liable to be rebuilt as separate vendors: eRAD (radiology information systems and picture archiving, now rebranded into Diagnostic Suite and Operations Suite), the original DeepHealth breast AI company, Aidence (lung), Kheiron (breast), Quantib (prostate and brain), See-Mode (thyroid and vascular ultrasound), iCAD (acquired July 2025 for a reported 103 million dollars, bringing the ProFound Breast Health Suite covering detection, density, risk and breast arterial calcification), CIMAR UK (cloud image management, acquired November 2025) and Gleamer SAS (Paris, acquired 2 March 2026, all cash, up to 230 million euros comprising about 215 million at closing plus a 15 million contingent milestone, bringing musculoskeletal, chest and neuro radiograph AI including BoneView). Gleamer retains its own record at [[gleamer]] because it still carries a distinct brand, product line and customer base. The portfolio is anchored on DeepHealth OS, a cloud native operating system, and divides into enterprise imaging (Diagnostic Suite, a picture archiving replacement; Operations Suite, covering scheduling, registration, billing and analytics; TechLive for remote multimodality scanning; Reporting Pro) and population health clinical AI (Breast Suite, including SmartMammo Dx, also known as Saige-Dx, with density, risk and breast ultrasound modules, plus Chest, Prostate, Neuro and Thyroid suites). Company published scale, combined with Gleamer: more than 2,700 customer contracts across more than 50 countries, 26 FDA cleared and 22 CE marked devices, more than 300 screening sites and more than 10 million mammograms a year. Third party traction is disclosed separately, with more than 16 million dollars of total contract value in new business signed in the first quarter of 2026, and named external customers including ONRAD, which serves more than 120 hospitals and radiology groups, and Wichita Radiological Group. The evidence base is led by the ASSURE study, published in Nature Health in November 2025 (Louis et al., doi 10.1038/s44360-025-00001-0), a prospective analysis of 579,583 women across more than 100 community imaging sites in four states. It compared an AI driven workflow (208,891 examinations) against the prior standard of care (370,692) and reported a 21.6 percent increase in cancer detection rate, 5.6 against 4.6 per thousand, with no significant variation across socio demographic or breast density subgroups and a 22.7 percent gain in women with dense breasts. Co authors include external academic investigators alongside RadNet's chief science officer. The comparison is against historical control rather than randomised, and the sites are substantially RadNet's own, which is addressed on the evidence axis.

care.ai turns patient rooms into sensed environments for virtual nursing and virtual monitoring, using camera based sensors with graphics processing units on the unit itself, so computer vision runs at the bedside rather than in a distant cloud. From a single virtual command centre, remote nurses or sitters support the bedside team, and Stryker states that one remote nurse can monitor, assess and support up to ten patients at once using the real time data the ambient system produces. The company was based in Orlando, Florida and was acquired by Stryker in 2024 for an undisclosed sum. It no longer trades independently, and this record is scoped to the care.ai product line, which Stryker continues to market under that name. What has changed since is the context around it. In March 2026 Stryker launched its SmartHospital Platform, run by a newly formed Smart Care business, which brings care.ai's ambient intelligence and virtual care workflows together with more than 85 Stryker products on one interface. Those include the ProCuity bed, the Vocera hands free communication devices and Sync Badge that Stryker acquired for close to 3 billion dollars in 2022, and the Engage middleware engine that filters and prioritises alarms. Vocera alone integrates with more than 150 clinical and operational systems including record systems, nurse call, ventilators and physiological monitors. So a hospital evaluating this is no longer evaluating an ambient intelligence vendor. It is evaluating one module of a medical device manufacturer's connected ecosystem, sold modularly but designed to be adopted together, and the more of that ecosystem a hospital already owns the more the ambient layer is worth to it. Anyone searching for care.ai or Vocera is looking at Stryker.

LeanTaaS sells capacity optimisation software to hospitals under the iQueue brand, forecasting demand and rescheduling scarce assets so that fewer of them sit idle. The name is short for Lean Transformation as a Service, and the company was founded in 2010 in Santa Clara, California by Mohan Giridharadas, previously a senior partner at McKinsey who led its lean operations practice in North America and Asia Pacific. The products address three assets that constrain hospital throughput. iQueue for Operating Rooms reallocates surgical block time, a problem the company states it first solved at UCHealth. iQueue for Infusion Centers schedules chemotherapy chairs, which began as a partnership with Stanford Health Care. iQueue for Inpatient Flow manages bed capacity, a capability strengthened by the acquisition of Hospital IQ. In 2024 the company added iQueue Autopilot, described as the first generative artificial intelligence product for hospital operations. The underlying mechanism is described as patented optimisation algorithms combining lean principles, predictive and prescriptive analytics and simulation. The scale is the largest of any operations vendor in this index. Nearly 200 health systems across more than 1,200 hospitals use one or more products, covering more than 5,600 operating rooms, 14,500 infusion chairs and 23,000 inpatient beds. Named customers include Stanford Health Care, UCHealth, UCSF, NewYork Presbyterian and Intermountain Health. A partnership with Siemens Healthineers was announced to optimise operational performance. KLAS named it Best in KLAS for Capacity Optimization Management in 2026 with a score of 95.6 out of 100, the highest in its category, having also won the category the previous year. The company has raised roughly 250 million dollars across ten rounds from investors including Insight Partners and Goldman Sachs, reports annual contract value approaching 150 million dollars and 170 percent revenue growth over three years, employs around 400 people, and has taken private equity investment from Bain Capital.

Fabric sells what it calls a care enablement system: conversational intake, triage, routing and treatment across virtual and in person care, sold to health systems, health plans and employers. It was founded in 2021 as Florence by Aniq Rahman, is based in New York, and rebranded to Fabric in 2024. The company is a roll up and that is the most important thing to understand about it. Five acquisitions in under three years assembled the product: Zipnosis, an asynchronous virtual care platform bought from Bright Health in April 2023; GYANT, a conversational artificial intelligence and patient engagement company bought all cash in January 2024, whose co founder Stefan Behrens became chief strategy officer; MeMD, bought from Walmart, which added payer and employer distribution; and TeamHealth Virtual Care, which added a 50 state clinical network of actual clinicians. Anyone searching for Zipnosis, GYANT or MeMD as separate companies is looking at brands that now sit inside this one. The product is organised as three suites covering in person care, virtual care and engagement, with a layer the company calls Hybrid AI that pairs conversational models with physician authored clinical logic and customisable decision trees. It raised a 60 million dollar Series A in February 2024 led by General Catalyst with Thrive Capital, GV, Salesforce Ventures, Vast Ventures, BoxGroup and Atento Capital, taking total funding past 80 million dollars. Named customers include OSF HealthCare, MUSC Health, Luminis Health and Intermountain, and the company stated coverage of more than 100 million lives as of September 2024. Published operational claims include clinicians working two to ten times faster depending on setting and a 15 percent reduction in call centre volume, and the acquired asynchronous product was described as automating 99 percent of administrative work with low acuity conditions treated in 89 seconds.

Artisight sells a smart hospital platform that turns a patient room into a sensed environment. A multi sensor network of cameras, microphones and positioning hardware runs computer vision and speech models on graphics processing units installed on site, and the system continuously observes the room and responds to what it sees and hears. The capability list spans several jobs the index usually treats separately: virtual nursing, virtual observation in place of an in person sitter, fall prevention, ambient documentation of room activity, two way audio and video for tele consultation, vital sign monitoring, indoor positioning, and surgical case length prediction in the operating room. The company describes itself as an ambient intelligence platform deployed across clinics, patient rooms and operating rooms rather than as a point solution. It was founded in 2015 by Andrew Gostine, a physician, and is based in Chicago. It raised a 42 million dollar Series B in January 2024 that was oversubscribed and included NVIDIA among the investors, followed by a further 40 million dollars reported in August 2025, at which point the platform was described as in use at 417 hospitals including Northwestern Medicine, WellSpan and the Guthrie Clinic. A notable feature of the capital structure is that many client hospitals are also investors. Northwestern Medicine is cited as reporting an 89 percent reduction in falls, a 52 percent reduction in nursing overtime and a 76 percent reduction in nursing turnover. In 2024 the chief executive stated that publication of these results in the peer reviewed literature was anticipated. No such publication was located in this pass.

Sickbay, from Medical Informatics Corp, is not a risk model. It is the data layer that risk models run on, and it is included in this category because it is FDA cleared for inpatient patient monitoring and alarm analytics and because its argument bears directly on how every other vendor here should be evaluated. The company's position is that the substrate is the problem. Predictive analytics in hospitals are typically built from discrete data points in the electronic medical record, which MIC argues are incomplete, significantly delayed and subject to human error, so predictions arrive after deterioration or are simply wrong. Sickbay's answer is to capture high fidelity, time series waveform data directly from bedside devices in near real time, at a stated average resolution of around 25 milliseconds per patient, and to persist it. Medical device manufacturers store data in proprietary formats, so the platform's central claim is vendor neutrality: it unlocks waveform and vitals data across disparate manufacturers, including from non networked devices such as ventilators, and makes it available through a browser on laptops, mobile devices, wallboards and in on premise or remote command centres. Crucially for how it is graded here, Sickbay supplies data to clinicians, researchers and algorithm developers through APIs and development tools rather than supplying its own deterioration model. Risk indicators in the Virtual Ops module are configurable by the institution. The platform received FDA 510(k) clearance as a Class II device along with three applications: Patient Monitor, Patient Alarm Data and Alarm Analytics Dashboard. The last of those is the only cleared product in this category aimed specifically at measuring alarm burden, which is this category's defining failure mode. Current modules are Sickbay core, Sickbay Telemetry, Sickbay Virtual Ops and Sickbay Analytics, with a dedicated rural healthcare offering. The company states any bed can be scaled to a monitored ICU bed within minutes through a database change. MIC is based in Houston and led by chief executive Emma Fauss, with Craig Rusin as chief product and innovation officer, whose research produced the grid computing platform underlying the product. Funding includes a Series A led by DCVC with Intel Capital and the Texas Medical Center Venture Fund, and a later 27 million dollar round co led by Catalio Capital Management and Intel Capital. Named institutional relationships include Texas Children's Hospital and Tampa General Hospital. Pricing is not published.

Proximie began as a way for a surgeon to virtually scrub in to any operating room and has become an operating system for the OR built on the data that capability generates. The original product is augmented reality telepresence: a remote expert joins a live procedure with full audio and video, annotates the surgical field, and observes, advises or teaches in real time, with every case recorded and indexed into a secure library for debrief, coaching and structured video review. On top of that sits the Intelligence Suite, described by the company as an ambient AI infrastructure layer that continuously captures intraoperative video, workflow activity imagery and instrument data across hundreds of facilities. In April 2026 Proximie joined NVIDIA's Project Rheo, building its Smart OR platform on NVIDIA foundation models while contributing real world surgical data back to inform NVIDIA's next generation healthcare models. The company reports deployment in more than 500 hospitals across 50 countries and five continents, more than 20 peer reviewed publications, and platform users seeing operating room productivity improve by up to 24 percent, which it frames as up to 300 additional procedures per room per year through better workflow visibility and more accurate prediction of surgery duration. Proximie was founded in 2016 by Dr Nadine Hachach-Haram, a practising NHS consultant plastic surgeon, and raised an 80 million dollar Series C with SoftBank participation. It is also lead author of a report on patient safety in surgery and the case for reform in the NHS.

Caresyntax is a vendor neutral enterprise surgical data platform that instruments the operating room and analyzes what it captures. Proprietary software and AI process video, audio, images, connected device output, clinical records and operational data from before, during and after a procedure, feeding real time support to the team in theatre, a telehealth link for people outside it, and post procedure analytics afterwards. The company sells the same data asset to four different buyers, which is unusual and shapes how the platform should be read: hospitals use it for operating room efficiency and throughput, surgeons for benchmarking and technique review, medical device manufacturers for product development evidence, and insurance companies for surgical risk assessment and policy design. Scale is substantial, with software in more than 4,000 operating rooms worldwide supporting over 30,000 surgical professionals across more than two million procedures a year. Caresyntax is headquartered in Boston and raised a 180 million dollar Series C extension in August 2024, comprising 80 million in equity and a 100 million growth debt facility, from investors including Optum Ventures, BlackRock Innovation Capital, Intel, and the medical liability insurers ProAssurance and Relyens. It also partners with Google Cloud.

Clinical risk platform running real time machine learning models inside hospital EHRs to detect deteriorating patients, with early sepsis warning as the flagship use case and additional configured uses spanning clinical deterioration, pressure injuries, palliative care, and transitions of care. A Johns Hopkins spinout founded on roughly a decade of academic research, it is one of very few clinical AI vendors whose deployed system has been evaluated in large prospective multi site studies published in peer reviewed journals.

Hospital operations automation platform applying machine learning, generative AI, and behavioral science to predict operational bottlenecks and act on them inside the EHR. Three solution lines address inpatient capacity and discharge planning, perioperative care coordination, and surgical growth and operating room utilization. An AI Solution Factory lets health systems co develop custom operational assistants for additional workflows.

Inpatient virtual care platform, and the first vendor in this index covering AI assisted virtual nursing and virtual sitting inside the hospital rather than in the home. The platform is modular: AI Assisted Virtual Nursing supporting virtual rounding, admissions, and discharges; AI Assisted Virtual Sitting and Patient Safety Monitoring, where the AI models cover fall prevention, fall detection, and pressure injury prevention; plus ambient documentation, patient engagement, digital whiteboards and room signage, hospital at home, remote patient monitoring, and a digital clinic. Hardware is part of the offering, including smart carts and in wall fixed devices providing video in the patient room. The stated design intent is extending clinical capacity rather than replacing staff: continuous monitoring across multiple units simultaneously so a smaller number of nurses can observe more rooms and intervene earlier. Reported adoption grew from more than 70 US health systems in February 2026 to more than 100 by June 2026. Named enterprise deployments include Ardent Health (NYSE: ARDT) across more than 2,000 patient rooms, MultiCare Health System as its enterprise virtual care platform, and One Brooklyn Health. Headquartered in Clearwater, Florida.

Healthcare data and agentic artificial intelligence platform, described by the company as an agentic cloud for healthcare, built in three stages: data connectivity integrating major electronic health record systems with payer claims, pharmacy, laboratory, remote monitoring and social determinants sources; applications on top of that data; and autonomous agents on top of those. Gravity is the underlying data and intelligence platform, described as continuously trained on real world healthcare data including claims denials and edge cases, which the company argues gives each new agent institutional context at launch. Sara is the assistant line spanning insights, care management and clinical documentation through Sara Scribe. Named agent products now include Provider Copilot with pre visit summary and ambient scribing, an agentic access centre, and Flow Auth for prior authorisation automation. The product estate has widened considerably through five acquisitions. Humbi AI added actuarial intelligence, Cured added a healthcare native customer relationship platform, Pharmacy Quality Solutions added pharmacy quality, Story Health arrived in September 2025 bringing continuous specialty care delivered by live health coaches working alongside agents with remote biometric monitoring, and CaduceusHealth was acquired in May 2026, a revenue cycle management services provider whose United States based team serves nearly 4,000 providers and manages five billion dollars in gross patient charges annually. That last acquisition extended the Flow suite into full stack revenue cycle operations for ambulatory care. On the payer side, Galaxy is the risk adjustment and analytics platform, joined by a Galaxy utilisation management product for health plans. Independent validation is the strongest in this index and is current. In the 2026 Best in KLAS awards the company took the top score in three categories: Gravity at 93.2 for data analytics platform for providers against a market average of 83.9, Galaxy at 90.5 for data analytics platform for payers against an average of 87.2, and Cured at 90.1 for customer relationship management platforms, its third consecutive win in that category. Scores derive from validated interviews with customers rather than vendor submissions. Infrastructure partnerships are named rather than implied, spanning a multi year strategic collaboration with Amazon Web Services, validated partner status with Databricks, and a partnership with Snowflake. A joint centre of excellence with a services firm and an alliance in the United Arab Emirates announced in April 2026 extend delivery capacity and international reach. Customers include Kaiser Permanente, Ascension and Trinity Health, with six of the top 10 United States health systems reported, alongside Carina Health Network covering more than 1.5 million Coloradans, a five year engagement with Community Care of North Carolina, and a virtual heart failure programme with Allina Health Minneapolis Heart Institute. Founded 2014, headquartered in San Francisco, 675 million dollars raised including a 275 million dollar Series F, with Kaiser Permanente and Banner Health among investors while also being customers. Two things a reader should weigh. The Centers for Medicare and Medicaid Services accepted the company's application under Story Health Partners for the Advancing Chronic Care with Effective, Scalable Solutions model, positioning it to participate at the programme's July 2026 launch across both cardio kidney metabolic tracks. Taken together with a revenue cycle services acquisition and a coaching based care model, the company is moving from selling software to health systems toward operating care and delivering services with people. That is the shape this index screens out when it constitutes the whole business, and it does not here, because the platform remains licensable on its own terms. It is a direction worth watching rather than a finding. And no pricing of any kind was located.

AI agent platform for healthcare operations, spanning patient access, revenue cycle, and care operations rather than a single workflow. Agents automate patient intake and registration, appointment scheduling, insurance eligibility verification, prior authorization, denial management, patient payment estimates, referral processing, and post visit follow up, each running a defined workflow end to end. Flow Builder is a no code interface that lets an organization's own IT and non technical staff build, train, and deploy agents, which places it alongside Bunkerhill and XCaliber as a build your own platform rather than a fixed product set. Integration is unusually pragmatic and is the stated differentiator: the company uses whichever method reaches the field, including APIs, RPA, and HL7, reading and writing structured and unstructured data across Epic, Oracle Health, MEDITECH, athenahealth, and payer portals. Named health system deployments include Intermountain, Trinity Health, and MUSC. Published customer results include a health system reaching 64 percent voice containment with roughly $360,000 annual savings, and an insurance FAQ voice assistant answering all inbound calls at a stated $4 saving per call. Backed by Greylock and ICONIQ Growth.

Multi agent platform automating clinical and administrative workflows from a single interface, with a coordinated network of role specific agents: an AI Receptionist handling inbound and outbound calls, scheduling, and patient communication; an AI Medical Assistant running intake, triage, and history capture; an AI Scribe producing real time documentation with ICD-10 and CPT evidence links; AI Coder and Biller agents for coding and revenue cycle; and an AI Inbox Manager working refills, messages, labs, and follow ups. States bidirectional integration with Epic, Cerner, and Allscripts and HIPAA compliance, with paperless intake syncing to the EHR. Marketed on reduced clinical support staff cost and shorter patient wait times, with stated attention to rural and underserved providers. Founded 2023 in Bellevue, Washington; emerged from stealth in late 2025 with a seed round. Early stage, and the breadth of the agent roster should be weighed against how recently the company began selling.

Agentic operating system positioned as a coordination layer across the systems a provider already runs rather than a replacement for them, on the premise that health systems accumulated EHRs, billing platforms, and scheduling tools over two decades without ever acquiring a layer to coordinate between them. Merlin is the role based agent line, and Patient Navigator, the first shipped agent, spans scheduling, prescription refills, outreach, intake, referrals, prior authorization, and billing resolution. The architecture is deliberately semi autonomous: agents run routine administrative workflows end to end and act across silos in real time, while a human in the loop structure keeps teams in control of critical decisions, with the degree of autonomy varying by whether a task is operational or clinical. The platform blends generative AI with traditional machine learning and microservices so deterministic tasks stay deterministic. Reports processing more than 8 million chart updates and generating over 160,000 EHR updates daily across more than 700,000 unique patients, with the navigator agent saving providers an average of six hours of manual work per day on refills alone. EHR integrations include Epic, Cerner, athenahealth, and eClinicalWorks, with listings on the athenahealth and AVIA marketplaces. Led by co founder and CEO Prakash Khot, previously a co founder of Skyflow; $6.5 million seed announced May 2026. Headquarters is reported as Andover, Massachusetts in funding announcements and as Plano, Texas by Crunchbase; this record does not resolve the discrepancy.

Clinical AI for imaging triage, delivered through aiOS, an enterprise AI operating system that handles data normalization, continuous performance monitoring, and governance so health systems can run multi condition AI without re architecting infrastructure. In January 2026 the FDA cleared what the company describes as healthcare's first comprehensive AI triage solution, powered by CARE (Clinical AI Reasoning Engine), its self developed foundation model. The clearance brought 11 newly cleared indications together with three previously cleared into a single abdomen CT workflow, 14 in total, and per the FDA reviewed pivotal study the new indications reported a mean sensitivity of 97 percent and mean specificity of 98 percent, with the company reporting roughly an order of magnitude reduction in false alerts against single condition tools. The company reports more than 100 million patient cases analyzed on aiOS. A successor model, CARE2, has been announced, and a multi year collaboration with Amazon Web Services supports the foundation model work. Co founded and led by Elad Walach.

Agentic AI platform for health systems. Carebricks lets clinical and operational teams build, deploy, and govern their own AI agents across clinical, operational, and administrative workflows rather than buying a point solution per use case. Agents in production include coronary calcium detection on routine chest CT, nephrology triage, lung nodule follow up, referral prioritization, prior authorization packet assembly, and registry automation. The company develops its own FDA cleared imaging algorithms that run inside the platform, including algorithms for coronary artery calcium and aortic valve calcium on contrast enhanced non gated chest CT, mitral annular calcification, and bone mineral density. CMS established a national billing code and OPPS payment for algorithmic CAC and AVC analysis on chest CT effective April 1, 2026. In production at Cleveland Clinic, the University of Texas Medical Branch, Intermountain Health, and Mayo Clinic. Founded by Nishith Khandwala, previously a researcher at Stanford's Center for Artificial Intelligence in Medicine and Imaging.